Mithra Acquires 100% Rights of Myring and Zoreline® and Closes first Distribution Deal

• Mithra buys 50% of Novalon SA
• Mithra (Novalon) buys back rights relating to Zoreline® and Myring (therapeutic equivalent products of branded products having realized, in 2014, worldwide sales in excess of 1.6 billion EUR) from GSP
• Mithra (Novalon) concludes its first commercialisation partnership for Zoreline® for selected countries

Liège, Belgium, 08 December 2015 – REGULATED INFORMATION- Mithra and GSP are pleased to announce that they have entered into a number of transactions by which Mithra has acquired the complete ownership of Novalon SA, the company which develops the projects Zoreline® and Myring, which are therapeutic equivalents to branded products which, in 2014, realized aggregate worldwide sales in excess of 1.6 billion EUR, as well as the global rights to these products. In parallel, they have entered into the first distribution deal for selected countries in respect of Zoreline®.

Read the press release

Mithra Pharmaceuticals reageert op ongefundeerde uitlatingen in de pers

Mithra Pharmaceuticals en haar Raad van Bestuur wensen vandaag volledige transparantie te geven ten aanzien van bepaalde ongefundeerde en gratuite uitlatingen in een bepaald deel van de pers.

Het persbericht lezen

Mithra neemt nota van de beslissing in kortgeding en zal verder haar rechten doen gelden

Mithra neemt nota van de beslissing in kortgeding uitgesproken op 1 december 2015 tussen het tijdschrift Médor en Mithra, die in de tegenovergestelde zin gaat van de beslissing die door een andere magistraat werd genomen op 18 november 2015.

Het persbericht lezen